Doern G V, Heilmann K P, Huynh H K, Rhomberg P R, Coffman S L, Brueggemann A B
Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa 52242, USA.
Antimicrob Agents Chemother. 2001 Jun;45(6):1721-9. doi: 10.1128/AAC.45.6.1721-1729.2001.
A total of 1,531 recent clinical isolates of Streptococcus pneumoniae were collected from 33 medical centers nationwide during the winter of 1999--2000 and characterized at a central laboratory. Of these isolates, 34.2% were penicillin nonsusceptible (MIC > or = 0.12 microg/ml) and 21.5% were high-level resistant (MIC > or = 2 microg/ml). MICs to all beta-lactam antimicrobials increased as penicillin MICs increased. Resistance rates among non-beta-lactam agents were the following: macrolides, 25.2 to 25.7%; clindamycin, 8.9%; tetracycline, 16.3%; chloramphenicol, 8.3%; and trimethoprim-sulfamethoxazole (TMP-SMX), 30.3%. Resistance to non-beta-lactam agents was higher among penicillin-resistant strains than penicillin-susceptible strains; 22.4% of S. pneumoniae were multiresistant. Resistance to vancomycin and quinupristin-dalfopristin was not detected. Resistance to rifampin was 0.1%. Testing of seven fluoroquinolones resulted in the following rank order of in vitro activity: gemifloxacin > sitafloxacin > moxifloxacin > gatifloxacin > levofloxacin = ciprofloxacin > ofloxacin. For 1.4% of strains, ciprofloxacin MICs were > or = 4 microg/ml. The MIC(90)s (MICs at which 90% of isolates were inhibited) of two ketolides were 0.06 microg/ml (ABT773) and 0.12 microg/ml (telithromycin). The MIC(90) of linezolid was 2 microg/ml. Overall, antimicrobial resistance was highest among middle ear fluid and sinus isolates of S. pneumoniae; lowest resistance rates were noted with isolates from cerebrospinal fluid and blood. Resistant isolates were most often recovered from children 0 to 5 years of age and from patients in the southeastern United States. This study represents a continuation of two previous national studies, one in 1994--1995 and the other in 1997--1998. Resistance rates with S. pneumoniae have increased markedly in the United States during the past 5 years. Increases in resistance from 1994--1995 to 1999--2000 for selected antimicrobial agents were as follows: penicillin, 10.6%; erythromycin, 16.1%; tetracycline, 9.0%; TMP-SMX, 9.1%; and chloramphenicol, 4.0%, the increase in multiresistance was 13.3%. Despite awareness and prevention efforts, antimicrobial resistance with S. pneumoniae continues to increase in the United States.
1999 - 2000年冬季,从全国33个医疗中心共收集了1531株近期临床分离的肺炎链球菌,并在一个中心实验室进行特性分析。在这些分离株中,34.2%对青霉素不敏感(MIC≥0.12μg/ml),21.5%为高水平耐药(MIC≥2μg/ml)。随着青霉素MIC的增加,所有β-内酰胺类抗菌药物的MIC也增加。非β-内酰胺类药物的耐药率如下:大环内酯类,25.2%至25.7%;克林霉素,8.9%;四环素,16.3%;氯霉素,8.3%;甲氧苄啶-磺胺甲恶唑(TMP-SMX),30.3%。青霉素耐药菌株对非β-内酰胺类药物的耐药性高于青霉素敏感菌株;22.4%的肺炎链球菌为多重耐药。未检测到对万古霉素和奎奴普丁-达福普汀的耐药性。对利福平的耐药率为0.1%。对七种氟喹诺酮类药物的测试结果显示体外活性的排序如下:吉米沙星>司帕沙星>莫西沙星>加替沙星>左氧氟沙星 = 环丙沙星>氧氟沙星。对于1.4%的菌株,环丙沙星的MIC≥4μg/ml。两种酮内酯类药物的MIC90(抑制90%分离株的MIC)分别为0.06μg/ml(ABT773)和0.12μg/ml(泰利霉素)。利奈唑胺的MIC90为2μg/ml。总体而言,肺炎链球菌中耳液和鼻窦分离株中的抗菌药物耐药性最高;脑脊液和血液分离株的耐药率最低。耐药分离株最常从0至5岁的儿童以及美国东南部的患者中分离得到。本研究是此前两项全国性研究的延续,一项在1994 - 1995年,另一项在1997 - 1998年。在过去5年中,美国肺炎链球菌的耐药率显著上升。1994 - 1995年至1999 - 2000年期间,选定抗菌药物的耐药性增加情况如下:青霉素,10.6%;红霉素,16.1%;四环素,9.0%;TMP-SMX,9.1%;氯霉素,4.0%,多重耐药性的增加为13.3%。尽管人们有所认识并开展了预防工作,但在美国,肺炎链球菌的抗菌药物耐药性仍在继续上升。